7TEU
Crystal structure of JAK2 JH1 with type II inhibitor YLIU-04-105-1
Summary for 7TEU
Entry DOI | 10.2210/pdb7teu/pdb |
Descriptor | Tyrosine-protein kinase JAK2, 3-{(4S)-2-[(cyclopropanecarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}-N-{3-[(4-ethylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl}-4-methylbenzamide, GLYCEROL, ... (4 entities in total) |
Functional Keywords | jak2, tyrosine kinase, inhibitor, cytokine signaling, transferase, transferase-inhibitor complex, transferase/inhibitor |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 1 |
Total formula weight | 37788.09 |
Authors | Hubbard, S.R. (deposition date: 2022-01-05, release date: 2023-06-21, Last modification date: 2023-10-25) |
Primary citation | Arwood, M.L.,Liu, Y.,Harkins, S.K.,Weinstock, D.M.,Yang, L.,Stevenson, K.E.,Plana, O.D.,Dong, J.,Cirka, H.,Jones, K.L.,Virtanen, A.T.,Gupta, D.G.,Ceas, A.,Lawney, B.,Yoda, A.,Leahy, C.,Hao, M.,He, Z.,Choi, H.G.,Wang, Y.,Silvennoinen, O.,Hubbard, S.R.,Zhang, T.,Gray, N.S.,Li, L.S. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. Cell Chem Biol, 30:618-, 2023 Cited by PubMed: 37290440DOI: 10.1016/j.chembiol.2023.05.007 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.45 Å) |
Structure validation
Download full validation report